Amgen Loses Battle In Anemia War With La Roche

Law360, New York (July 10, 2006, 12:00 AM EDT) -- Marking another chapter in an epic battle over the multi-billion dollar market for anemia treatments, an judge with the International Trade Commission has rejected Amgen Inc.'s bid to bar rival drugmaker Hoffman-La Roche Inc.’s U.S. importation of peg-EPO.

But the ITC’s ruling doesn’t give Hoffman-La Roche (Roche) a green light to manufacture and sell their anti-anemia drug CERA in the U.S. The ruling only allows Roche to import and use peg-EPO for use in clinical trials.

Amgen was quick to point out that the ITC’s decision...
To view the full article, register now.